Cerus Corporation to Participate in Upcoming Virtual Investor Conferences

Rhea-AI Summary

Cerus Corporation (Nasdaq: CERS) has announced that CEO William ‘Obi’ Greenman and CFO Kevin D. Green will participate in two upcoming conferences. The first event is the BTIG Virtual MedTech Conference on February 17 at 1:30 PM ET, followed by the Cowen 41st Annual Health Care Conference on March 1 at 2:40 PM ET. Both events will be webcast live, with replays available for two weeks post-event. Cerus focuses on enhancing blood safety through its INTERCEPT Blood System, which has received both CE mark and FDA approval for pathogen reduction in platelets and plasma.

Cerus Corporation (Nasdaq: CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin D. Green, Cerus’ chief financial officer, are scheduled to participate in two conferences:

• BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 17^th at 1:30 P.M. ET.
• The Cowen 41^st Annual Health Care Conference on Monday, March 1^st at 2:40 P.M. ET.

A live webcast of the events will be available on the Investor Relations page of the Cerus web site at http://www.cerus.com/ir. A replay will be available for approximately two weeks following the completion of the event.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210204005306/en/

FAQ

What is the schedule for Cerus Corporation's upcoming conferences?

Cerus Corporation will participate in the BTIG Virtual MedTech Conference on February 17 at 1:30 PM ET and the Cowen 41st Annual Health Care Conference on March 1 at 2:40 PM ET.

How can I watch the Cerus Corporation conference webcasts?

The conference webcasts of Cerus Corporation will be available on their Investor Relations page at http://www.cerus.com/ir.

What technologies does Cerus Corporation focus on?

Cerus Corporation develops technologies for safeguarding the blood supply, including the INTERCEPT Blood System for pathogen reduction in blood components.

Is the INTERCEPT Blood System approved by any regulatory bodies?

Yes, the INTERCEPT Blood System has received both CE mark and FDA approval for pathogen reduction in platelets and plasma.

When will the replay of Cerus Corporation's conference be available?

Replays of the Cerus Corporation conferences will be available for approximately two weeks after each event.